1. Unable to obtain informed consent from subject or LAR. <br/ > 2. Patients with ALT/AST â?¥ 5 x upper limit of normal (ULN). <br/ > 3. Patients with heart disease or clinical symptoms that cannot be well controlled, such as NYHA class II or above of cardiac insufficiency, unstable angina, myocardial infarction within one year, supraventricular or ventricular arrhythmias that need treatment or intervention. <br/ > 4. Allergic to Bevacizumab and its components. <br/ > 5. Treatment with immunosuppressive or immunomodulatory therapy (including bevacizumab) within the past 3 months. <br/ > 6. Platelet count of < 1,00,000 /cmm or absolute neutrophil count (ANC) < 2000/cmm at screening <br/ > 7. Respiratory failure due to other secondary infections /bacterial sepsis or evidence of multiorgan failure <br/ > 8. Clinical or laboratory evidence of active tuberculosis or active secondary infections. <br/ > 9. Subjects who are HIV, HBsAg, HCV test positive. <br/ > 10. Pregnant women, lactating women and planned pregnancy. <br/ > 11. Have participated in other clinical trials in the last 3 months or the investigator is of opinion that it is not in the best interest of patient to get enrolled in the study or any other condition wherein the patient participation would cause concerns about his / her safety.

1. Unable to obtain informed consent from subject or LAR. <br/ > 2. Patients with ALT/AST â?¥ 5 x upper limit of normal (ULN). <br/ > 3. Patients with heart disease or clinical symptoms that cannot be well controlled, such as NYHA class II or above of cardiac insufficiency, unstable angina, myocardial infarction within one year, supraventricular or ventricular arrhythmias that need treatment or intervention. <br/ > 4. Allergic to Bevacizumab and its components. <br/ > 5. Treatment with immunosuppressive or immunomodulatory therapy (including bevacizumab) within the past 3 months. <br/ > 6. Platelet count of < 1,00,000 /cmm or absolute neutrophil count (ANC) < 2000/cmm at screening <br/ > 7. Respiratory failure due to other secondary infections /bacterial sepsis or evidence of multiorgan failure <br/ > 8. Clinical or laboratory evidence of active tuberculosis or active secondary infections. <br/ > 9. Subjects who are HIV, HBsAg, HCV test positive. <br/ > 10. Pregnant women, lactating women and planned pregnancy. <br/ > 11. Have participated in other clinical trials in the last 3 months or the investigator is of opinion that it is not in the best interest of patient to get enrolled in the study or any other condition wherein the patient participation would cause concerns about his / her safety.